Boston Scientific is the maker of the Taxus stent, one of its blockbuster products. This week the company confirmed it had seen a statistically significant increase in such clotting n patients receiving its stent. Compared with patients getting bare-metal stents, an additional one in 200 is likely to develop a blood clot, the company said.
The clotting problem is a concern because blood clots can often be fatal. By contrast, the problem the stents are designed to fix, called restenosis, often leads to a repeat heart procedure but is not considered fatal.
Bare metal stents usually are problem free after the first thirty days.
Go here for more.
